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THE PREVALENCE OF 
INFECTIVE ENDOCARDITIS 
AFTER AORTIC VALVE 
REPLACEMENT 
Replacement valve endocarditis occurred in 3.7% of 2443 patients who 
underwent primary or redo aortic valve replacements at The Prince Charles 
Hospital between December 31, 1969, and January 1, 1992, based on a 
cross-sectional follow-up in 1992 which was 98.8% complete. Because some 
patients had re-replacements during the study period, a total of 2686 opera- 
tions were considered for analysis. A variety of replacement devices were used, 
including 571 allografts (21%), 1152 xenografts (43%), and 880 mechanical 
valves (36%). Insertion of an allograft valve resulted in a constant risk of 
endocarditis which, by multivariable hazard function analysis, negated the 
effect of any early-phase risk factors (p < 0.0001). With other replacement 
devices, the risk of infection peaked early after operation (9 weeks) and then 
gave way to a constant risk. Compared with the risk associated with allograft 
valves, constant risk was higher when the replacement device was a Carpen- 
tier-Edwards xenograft (n = 1021,p = 0.02) and lower when a St. Jude Medical 
mechanical valve was used (n = 505, p = 0.05). In nonallograft recipients, the 
presence of active preoperative endocarditis (p < 0.0001) or a concomitant 
synthetic aortic root replacement (p = 0.0006) increased the magnitude of the 
early peaking risk. Regardless of replacement device, constant risk was 
increased in patients with renal dysfunction (p = 0.01), in younger patients 
(p < 0.0001), and in those with active or healed preoperative endocarditis (p = 
0.04). When preoperative endocarditis was caused by Staphylococcus aureus, 
risk was higher than when it was caused by other organisms (p = 0.04). A 
culture-positive postoperative wound infection was associated with increased 
risk of replacement valve infection (p < 0.001) and when it occurred, the same 
organism was usually responsible (86%). Identification of patients at increased 
risk for replacement valve infection may lead to reduced morbidity through 
strategies uch as selective use of replacement devices and antimicrobial 
prophylaxis. (J THORAC CARDIOVASC SURG 1995;110:1708-24) 
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I nfective endocarditis is a serious and frequently fatal condition, particularly when it occurs on a 
valve replacement device. 1 In patients with active 
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endocarditis, the risk of recurrent infection may be 
lower when an allograft replacement valve is 
used. t'2 However, in patients undergoing aortic 
valve replacement (AVR)  for any reason, usually for 
reasons other than endocarditis, the prevalence of 
postoperative ndocarditis and the impact of re- 
placement with various modern devices has not been 
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fully character ized. Therefore  a study to determine 
the prevalence of  rep lacement  endocardit is  and its 
risk factors 'was undertaken in a series of pat ients 
undergoing AVR for any reason, in which a variety 
of rep lacement  devices were used. 
Patients and methods 
Study group. A total of 2443 patients had an isolated 
AVR at The Prince Charles Hospital (TPCH) from 
January 1, 19'70, to January 1, 1992. Among these 2443 
patients, 89 had their first AVR and 2 patients had their 
first two AVRs either before 1970 or at another institu- 
tion. Among the 2443, 290 (11.9%) had a second AVR at 
TPCH during 1:his period, 43 (1.8%) had a third, and i had 
a fourth, leading to a total of 2686 operations. Patients 
with previous mitral or tricuspid valve operations were not 
included. 
A concomitant procedure not involving valve replace- 
ment, most frequently coronary bypass grafting, was per- 
formed in 856 (32%) of the operations (Appendix Table 
1). The average patient age at first TPCH operation was 
56 years (+15 years, standard deviation), and 74% of 
patients were male. In 243 (9.0%) of the operations the 
patient had previous (preoperative) ndocarditis and the 
organisms involved are outlined in Appendix Table 2; in 
92 (38% of 243) of these cases active endocarditis was an 
indication for operation. Additional patient characteris- 
tics are outlined in Appendix Table 3. 
Operative technique. The usual methods of cardiopul- 
monary bypass were used for the operations. From 1967 to 
1978, myocardial protection was provided by continuous 
coronary perfusion, and from 1978 to 1992, by cold crystal- 
loid cardioplegia supplemented with topical cooling. 
A variety of replacement devices were used (Appendix 
Table 4), but biologic valves predominated (xenografts in 
43% of the operations, allografts in 21%), and some 
patients early in the experience received what would now 
be regarded as obsolete valves (fascia lata valves or 
Braunwald-Cutter prostheses, Cutter Biological, Berke- 
ley, Calif.). Mechanical and xenograft valves were inserted 
with an interrupted suture technique. Allograft valves 
were inserted by a variety of methods, 3 including the 
subcoronary technique, the cylindrical technique, and as 
an aortic root replacement. Valve selection was at the 
discretion of the surgeon, but an allograft aortic valve was 
more likely to have been inserted in the latter part of the 
experience. Abscess cavities were not specifically closed 
unless closure was necessary for anchoring of valve pros- 
theses. 
Routine postoperative antimicrobial therapy consisted 
of intravenous antibiotics for the first 2 days, then oral 
antibiotics for an additional 2 or 3 days. The antibiotics 
used were anapicillin/cloxacillin from January 1970 
through December 1979, ampicillin/flucloxacillin from 
January 1980 through August 1982, and cephalothin (i - 
travenously)/cephalothin (orally) from September 1982 
through January 1992. 
Definitions 
Preoperative endocarditis. Patients were considered to 
have had preoperative endocarditis f morphologic, histo- 
logic, or bacteriologic evidence of aortic valve infection 
was present at the time of their valve replacement. Such 
patients were subdivided into two groups. Patients with 
positive cultures of operative specimens or positive blood 
cultures in the immediate preoperative period were con- 
sidered to have active preoperative endocarditis. Patients 
lacking positive cultures, but with morphologic evidence 
of previous disease, were considered to have remote 
endocarditis, and an attempt was made to identify from 
the medical record the previous episode of endocarditis 
and the identity of the causative organism(s). 
Replacement valve endocarditis. Replacement valve en- 
docarditis was defined as infection occurring on the 
AVR device. Replacement valve infection was consid- 
ered to be present (1) if typical clinical symptoms of 
endocarditis developed, including fever, splenomegaly, 
peripheral skin or mucocutaneous lesions, or a regnr- 
grant  murmur, along with positive blood cultures with 
no obvious extracardiac source of infection, (2) if blood 
cultures were positive for infection with consistent 
findings at reoperation or autopsy, or (3) if organisms 
were cultured from the removed prosthetic valve at the 
time of reoperation. 4 
Two patients who had active native valve infection at 
the time of AVR continued to show clinical signs of valve 
infection in the early postoperative p riod, leading to an 
early diagnosis of replacement valve endocarditis. In these 
cases, the event endocarditis was considered to have 
occurred on the date of the first positive blood culture in 
the postoperative p riod. 
Data collection and follow-up. Information was ob- 
tained from hospital and outpatient medical records and 
by direct contact with the patients' families, local physi- 
cians, and cardiologists. Information was collected from 
January 15, 1992, through November 9, 1992. 
Of the 2443 patients. 2413 (98.8%) were either known 
to be dead or were contacted uring the follow-up inter- 
val. The remaining 30 patients were lost to follow-up at 
some time in their postoperative period, but only three 
were not contacted after hospital dismissal. The mean 
period from operation to most recent follow-up was 6.9 
years (83 months; standard eviation z 5 years). Seventy- 
five percent of patients were followed up for more than 15 
months. 50% for more than 5.7 years (68 months), and 
25% for more than 14 years (172 months). 
Data analysis. Simple contingency tables and com- 
parisons of means were made for all variables. Actuar- 
ial analyses were performed by the Kaplan-Meier meth- 
od. 5 The overall hazard function (instantaneous risk of 
endocarditis) was estimated by a generic three-phase 
model. 6 facilitating multivariable, parametric analysts 
of risk factors within individual phases of risk. 7 A p 
value of 0.1 was used as the criterion for retaining a 
variable in the model (this level was chosen because, 
despite the large number of operations, there were 
relatively few events), but for each identified risk factor 
the p valve is provided, allowing for independent as* 
sessment as to its believability. 
For the Kaplan-Meier estimates and for the multivari- 
able analysis, patients were censored at the ume of their 
death or at the time of a heart transplant (one patient). 
Because of the prevalence of more than one AVR. two 
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techniques were used for patients in the study group who 
had multiple AVRs. In one, each patient was entered into 
the data set once, at the time of the initial AVR 
procedure at TPCH. The patient was then followed up 
in the usual way (intention-to-treat analysis). In other 
words, crossovers were simply accepted2 This method 
had the number of patients as the N. The second 
method took account of the time-varying covariate of 
repeated AVRs by using the modulated renewal pro- 
cess. s In this process patients who underwent a second 
AVR were removed from the study group (censored)at 
the time of the Second replacement and were entered 
into a second study group in which time zero was the 
time of the second replacement. Those with a third 
AVR were censored and entered into a third study 
group, and so forth. This resulted in a complete depic- 
tion of the 2686 operations among the 2443 patients. 
The multivariable analysis was made of the composite 
group of 2686 operations by a modulated renewal process, 
which properly evaluated the possibility hat he time-varying 
covariate "AVR number" 2 or 3 (or more) was itself an 
incremental risk factor (explanatory variable). In this, pa- 
tients with an initial AVR elsewhere or before this study 
received avalue of "2" for "number of previous AVRs" in 
their first entry in the study. 
Patients who received allograft valves were found to 
have only a single constant phase of hazard (lacking the 
early phase present in patients who received other valves). 
In previous studies, discrepancies of this type precluded 
the inclusion of all operations in a single multivariable 
analysis, in part because of computational intractabilities 
introduced by the complete absence of a hazard phase. 2In 
this study, estimates when the allograft and nonallograft 
recipients were combined were not found to be intracta- 
ble, and the absence of an early phase in the former group 
was represented by a large negative Coefficient. The assump- 
tion was that a previously undetectable early phase of hazard 
was Present in the all0graft group. The analyses were re- 
peated with the allograft group evaluated independently and 
the results were found to be similar. In this manuscript 
results from the combined a.nalyses are presented. 
As a means of internal validation of the mu!tivariable 
model, Kapian-Me~er stimates were made of several 
subgroups, and solutions for the same groups of pa- 
tients were computed by averaging the indiv!dual pa- 
tient-spec!fic predictions from the multivariable qua- 
tion. The comparison was made in the time-related 
domain and also by comparing the total number of 
events (Appendix Table 5). 
Results 
Overall prevalence. The non-risk-adjusted actu- 
arial freedom (Fig. 1, A) from endocarditis among 
the 2443 patients followed up after their first AVR 
at TPCH was 94.6% at 10 years and 89.8% at 20 
years. The parametric estimate was similar, and its 
corresponding hazard function had two phases (Fig. 
1, B), with an early peak at 9 weeks that gave way to 
a constant risk by about 6 months after operation. 
Factors affecting the prevalence of replacement 
valve endocarditis. Patient and operative character. 
istics associated with an increased prevalence of 
replacement valve infection were identified by non- 
risk-adjusted (Appendix Tables 1, 3, and 4) and 
risk-adjusted (multivariable) analysis (Table I). 
Prereplacement endocarditis. The prevalence of 
replacement valve endocarditis was higher by non- 
risk-adjusted analysis in those with preoperative 
endocarditis than in those without it (Fig. 2). In 
risk-adjusted analyses, preoperative ndocarditis 
was associated with increased constant-phase haz- 
ard, but early-phase risk was increased only when 
there was active endocarditis at the time of AVR. 
The constant-phase risk was not equal for all pa- 
tients with preoperative endocarditis; risk was 
higher in patients with Staphylococcus aureus endo- 
carditis than in those with preoperative endocarditis 
caused by other organisms (p = 0.05) (Fig. 3). 
Replacement with an allografi valve. Regardless of 
the presence of early-phase risk factors, patients 
who received an allograft replacement device did 
not demonstrate an increased early risk of replace- 
ment valve endocarditis, having only a single (con- 
stant) risk. This negation of increased early risk is 
represented in the multivariable equation (see Table 
I) as a large negative coefficient in the early phase. 
Replacement with other devices. In non-risk- 
adjusted and risk-adjusted analyses, patients who 
received the now obsolete fascia lata valve had a 
higher prevalence of postoperative endocarditis at 
any time after operation. Late postoperative endo- 
carditis was less prevalent (p = 0.05) after AVR with 
a St. Jude Medical mechanical valve (St. Jude 
Medical, Inc., St. Paul, Minn.). In risk-adjusted 
analysis only, other valve-specific differences in risk 
were identified, including an increased constant- 
phase risk for endocarditis in patients receiving 
the Carpentier-Edwards xenograft valve (Baxter 
Healthcare Corp., Edwards Division, Santa Ana, 
Calif.) (see Table I). 
Figs. 4/1, 4B, and 4C depict he estimated freedom 
from replacement valve endocarditis after replace, 
ment with the three most commonly used devices in 
patients with differing preoperative endocarditis his- 
tories. 
Concomitant procedures. In risk-adjusted analy- 
sis, concomitant replacement of the aortic root with 
a synthetic graft (but not root replacement with 
tissue) was associated with a higher early risk of 
replacement valve endocarditis. Although the prev- 
alence of postoperative endocarditis after concomi- 
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Fig. L A, Time-related prevalence of freedom from endocarditis after first AVR at TPCH (n = 2443). 
Note :hat the vertical axis representing freedom from endocarditis (the complement of prevalence of 
endocarditis) is expanded. Circles represent the occurrence of endocarditis in an individual, positioned 
along the horizontal axis at the interval between operation and the time of occurrence and actuarially 
(Kaplan-Meier method) along the vertical axis. The vertical bars represent 70% confidence limits (_+1 
standard eviation). Numbers in parentheses represent the number of patients continuing to be followed up 
after that time. The solid line represents the parametrically estimated freedom from endocarditis, and the 
dashed line encloses the 70% confidence limits of that estimate. The table represents the parametric 
estimates at specified intervals. B, Hazard function for the rate of endocarditis (events/month) after the 
first AVR at TPCH. The horizontal axis is expanded for better visualization of the early risk. The hazard 
functien has two phases, an early peaking phase that gives way to the constant phase of hazard at about 5.5 
months. The depiction is similar to that in A. 
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Table I. Incremental risk factors for endocarditis after AVR (N = 2686; 95 events) 
Hazard phase 
Early Constant 
Risk factor Coefficient P Coefficient P 
Demographic 
Age (younger)* 
Clinical history 
Renal dysfunction 
Preoperative endocarditis 
! f Staph. aureus was the causative organism 
If active endocarditis at operation 
Replacement device 
Allograft 
Medtronic Intact 
Fascia lata 
Carpentier-Edwards 
St. Jude Medical 
Concomitant procedures 
Aortic root replacement with synthetic graft 
Support echnique 
3.526 <0.0001 
-13.17 <0.0001 
2.612 0.002 
2.081 0.01 
3.084 0.0006 
-0.9272 <0.0001 
1.005 0.01 
0.6686 0.04 
0.9026 0.05 
1.484 0.0001 
0.6154 0.02 
-2.062 0.05 
Bypass time (longer) 0.1898 0.01 
Intercept -6.207 <0.0001 -7.727 <0.0001 
Note: Age, in years, was tr nsformed as: age' = 2 = exp (age/50) . Bypass time, in minutes, was transformed as: bypass time' (bypass time/120). 
*Younger patients are at increased risk. 
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Fig. 3. Nomograms ( pecific solutions from the multivariable quation) depicting risk-adjusted freedom 
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a 50-year-old patient, without renal dysfunction, and with the preoperative history indicated. The lines 
represent the overall response for all replacement valve types. The confidence intervals arenot shown to 
improve clarity, but those for "no preoperative endocarditis" overlapped no others. 
tant mitral valve repair and concomitant false aneu- 
rysm closure was increased by non-risk-adjusted 
analysis (Appendix Table 1), during subsequent 
risk-adjusted analysis these differences were found 
to be explained by the prevalence of other patient- 
specific risk factors. 
Primary versus redo A VR. When examined in a 
non-risk-adjusted manner, primary AVR was fol- 
lowed by a lower prevalence of replacement valve 
endocarditis than was redo AVR (Wilcoxon p = 
0.03). The small group (n = 43) of patients having a 
second redo operation (the third AVR operation) 
did not haw ~, a believably higher non-risk-adjusted 
prevalence of postoperative endocarditis than those 
having their first redo operation (Wilcoxon p = 
0.76). However, redo AVR was not found to be a 
risk factor for replacement valve endocarditis in 
risk-adjusted analyses. This is likely a result of the 
differences in risk factors (explanatory variables) 
among those having primary and redo operations 
(Appendix Table 6). 
Age. Younger age at operation increased con- 
stant-phase risk (p < 0.0001). By correlation analy- 
sis, younger patients were more likely to be male 
(p = 0.00011) and were more likely to have had 
preoperative ndocarditis (p = 0.0001). When 
younger patients had preoperative endocarditis, the 
organism was more likely to be Coxiella burnetii (Q 
fever) than when older patients had preoperative 
endocarditis (p = 0.002). 
The association of postoperative complications to 
replacement valve endocarditis. The presence of a 
postoperative wound infection or postoperative car- 
diac dysfunction was associated with an increased 
prevalence of postoperative endocarditis (Appendix 
Table 7), even when adjustments were made for 
identified risk factors (Table II). Among the seven 
patients who had wound infections and later had 
endocarditis, the mean period from wound infection 
to diagnosis of endocarditis was 6 weeks. In six of 
the seven patients (86%) the organism cultured 
from the infected wound was subsequently respon- 
sible for the valve infection, and in the remaining 
patient endocarditis occurred many months after 
operation. Patients having an early reoperation for 
excessive bleeding (reentry) had a higher prevalence 
of replacement valve endocarditis, but this finding 
could be due to chance alone (p = 0.2). 
The prevalence of staphylococcal versus strepto- 
coccal replacement valve endocarditis. Staphylo- 
coccal organisms were most commonly responsible 
for postoperative endocarditis, followed by strepto- 
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Fig. 4A. Nomogram (specific solution from the multivariable quation) depicting risk-adjusted freedom 
from replacement valve endocarditis (risk adjusted) for a patient receiving a Carpentier-Edwards 
(xenograft) valve. Estimates were made for a 50-year-old patient, without renal dysfunction, who did not 
receive a concomitant aortic root replacement, and with the pre-replacement endocarditis history specified. 
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Table II. Correlates of endocarditis after A VR considering postoperative variables (N = 2686; 95 events) 
Hazard phase 
Early Constant 
Risk factor Coefficient P Coefficient P 
Demographic 
Age (younger) 
Clinical history 
Renal dysfunction 
Preoperative ndocarditis 
If Staph. aureus was the causative organism 
If active endocarditis at operation 
Replacement device 
Allograft 
Fascia lata 
Carpentier-Edwards 
St. Jude Medical 
Support technique 
Bypass time (longer) 
Postoperative course 
Wound infection 
Cardiac dysfunction 
Intercept 
3.045 <0.0001 
- 12.92 <0.0001 
2.731 0.005 
3.975 <0.0001 
3.052 <0.0001 
-7.244 <0.0001 
-0.9300 <0.0001 
0.9682 0.02 
0.6469 0.05 
0.8632 0.07 
1.465 0.0001 
0.5805 0.02 
-2.3188 0.08 
0.1929 0.01 
- 7.703 <0.0001 
Note: Age, in years, was transformed as: age' = (age/50) 2. Bypass time, in minutes, was transformed as: bypass time' = exp (bypass time/I20). 
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Table III. Causative organisms in postoperative 
endocarditis 
Organism n % of 95 
Gram positive 
Staphylococcus 36 37 
Staph. aureus 31 33 
Staph. epidermidis 3 3.2 
Unspecified 2 2.1 
Streptococcus 28 27 
S. viridans 6 6.3 
S. sanguis 8 8.4 
S. faecalis 4 4.2 
S. mitis 3 3.1 
Other Streptococcus* 3 3.1 
Unspecified sp. 4 4.2 
Corynebacterium 4 4.2 
Micrococcus 1 1.1 
Bacillus (otherwise unspecified) 1 1.1 
Gram negative 15 14.7 
CoxieIla burnetii 7 7.4 
Eikenella corrodens 2 2.1 
Pseudomonas p. 2 2.1 
Haemophilus p. 1 1.1 
Klebsiella pneumonia 1 1.1 
Neisseria gonorrhea 1 1.1 
Proteus mirabilis 1 1.1 
Mycotic 4 4.2 
Mucor sp. 2 2.1 
Aspergillus fumigatus 1 1.1 
Candida albicans 1 1.1 
Unidentified 9 8.4 
Note: Although organisms were not identified in nine patients, ome of the 
remaining 86 patients had polymicrobial infections, leading to a total of 98 
identified organisms. 
*Includes the following streptococcal species: boris (1), pneumoniae (1), 
and salivarius (1). 
coccal organisms (Table III). Staphylococcal endo- 
carditis tended to occur early after operation, 
whereas the risk of streptococcal infection was con- 
stant across time (Fig. 5). The risk of endocarditis 
caused by other organisms was similar to that for 
staphylococcal organisms. In a separate risk-ad- 
justed analysis of the event replacement valve staph- 
ylococcal endocarditis, patients with preoperative 
endocarditis were found to be at increased risk of 
staphylococcal endocarditis (p < 0.001) only if their 
preoperative infection was caused by a staphylococ- 
cal organism (Table IV). 
Mortality after AVR and diagnosis of replace- 
ment valve endocarditis. Among the 2443 patients, 
there were 678 deaths (28%) during the follow-up 
period. The actuarial freedom from death after a 
first AVR was 93.9% at 1 year, 84.3% at 5 years, 
65.7% at 10 years, and 37.6% at 20 years. Among 
the 93 patients in whom replacement valve endocar- 
ditis developed, there were 47 deaths (50.5%). Ac- 
tuarial survival after diagnosis of replacement valve 
endocarditis was 81.7% at 1 year, 58.2% at 5 years, 
and 37.1% at 10 years. 
Discussion 
Method. This analysis is made more specific by 
the use of parametric, phase-specific, multivari- 
able methods. These techniques have been used 
previously for the analysis of endocarditis after 
AVR.9, 10 In an attempt o increase clarity, but 
also for reasons of mathematical tractability, we 
have designated some characteristics a negative 
risk factors, instead of using positive coefficients 
and the absence of a characteristic. For example, 
we have designated use of allografi valve as a negative 
risk factor instead of nonuse of an allograft valve as a 
positive risk factor. 
Patients with previous nonaortic valve operations 
were not included in the study group. This exclusion 
was an attempt to eliminate ambiguity regarding the 
location of postoperative endocarditis n patients 
with clinical evidence of valve infection. For similar 
reasons, we excluded those with double valve oper- 
ations (concomitant on-AVRs) and censored pa- 
tients at the time of any subsequent valve replace- 
ment. 
This analysis does not address risk factors for 
mortality, reoperation, or morbidity (other than 
endocarditis). Admittedly, such information would 
be prerequisite to definitive recommendations re-
garding treatment s rategies, uch as valve selection 
for particular patients, because replacement valve 
endocarditis i  a relatively uncommon cause of 
morbidity or mortality. 
Prevalence of replacement valve endocarditis. 
The overall estimate of incidence of prosthetic valve 
endocarditis in this report is low (3.8%) and consis- 
tent with data from previous reports. 11-14 In actuar- 
ial estimates, we censored patients at the time of 
death, reoperation, or non-AVR. It is important to 
remember that the reported actuarial estimates 
cannot be used independently o estimate a percent- 
age of patients in whom endocarditis will develop. 15 
For example, although the actuarial occurrence of 
endocarditis at20 years is 9.7%, the expected num- 
ber of endocarditis cases for a large group of 
patients followed up for 20 years would be less than 
9.7%, because some patients will die and still others 
will have reoperations before endoearditis develops. 
Recurrent endocarditis. Previous work has 
shown that patients with preoperative (native or 
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Fig. 5, Separately determined hazard functions for the non-risk-adjusted rate of staphylococcal and 
streptococcal endocarditis. The horizontal axis is expanded to allow better visualization of early phase 
differences. Solid lines represent he hazard estimates, and the corresponding dashed lines enclose 70% 
confidence limits. Note that the risk of staphylococcal endocarditis is increased early after the operation 
and that the constant-phase risk is similar for staphylococcal nd streptococcal endocarditis. 
Table IV. Risk factors for staphylococcal endocarditis after AVR (N = 2686; 36 events) 
Hazard phase 
Early Constant 
Risk factor Coefficient p Coefficient p 
Demographic 
Age (younger)* 
Clinical hisl:ory 
Diabetes 
Number of previous aortic valve operations 
Renal dysfunction 
Preoperative ndocarditis with 
Staph. aureus (active or remote) 
2.733 0.005 
1.248 0.06 
-0.9939 <0.007 
1.596 <0.001 
2.567 <0.0001 
Intercept -6.633 <0.0001 -8.136 <0.0001 
Note: Age, in years, was transformed as: age' = (age/50) 2. Renal dysfunction was defined as creatine concentration greater than or equal to 0.2 mmol/L at 
last blood test before operation. 
*Younger patients were at increased risk. 
replacement) endocarditis are at increased risk for 
postoperative ndocarditis, 11'15 and this analysis 
further stratifies this risk by identifying two impor- 
tant characteristics of patients with preoperative 
endocarditis: the causative organism (Staphylococ- 
cus aureus or other) and the infection status at the 
time of valve replacement (active or remote). These 
characteristics lead to four possible risk categories 
for those with preoperative infection: (1) active 
Staphylococcal ureus infection, (2) active infection 
with an organism other than Staphylococcus aureus, 
(3) remote Staphylococcus aureus infection, and (4) 
remote infection with an organism other than Staph- 
ylococcus aureus (see Fig. 3). 
That active valve infection, but not remote, in- 
creases the early-phase risk of replacement valve 
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infection suggests that in some patients with active 
preoperative endocarditis the infection persists into 
the postoperative p riod. These findings upport he 
concept hat an allograft valve is indicated in the 
face of active endocarditis. 2 
Constant-phase risk of recurrent endocarditis was 
found to be increased in all patients with previous 
endocarditis, but the magnitude was dependent on 
the infecting organism. Preoperative Staphylococcus 
aureus infection increased the constant risk more 
than infection with other organisms. From a sepa, 
rate analysis of risk factors for staphylococcal endo- 
carditis, we found that another staphylococcal infec- 
tion tended to recur. This apparent predisposition to
valve infection, most pronounced in those who had 
staphylococcal endocarditis, has been suggested 
previously. 1 Such a recurrence tendency might be 
expected in patients who are prone to recurrent 
bacteremias, such as persons who abuse intravenous 
drugs or those with chronic skin infections (e.g., 
carbunculosis). Alternatively, this tendency to recur- 
rence might reflect subtle difference in immunologic 
susceptibility, 16 perhaps otherwise clinically insignif- 
icant, which predispose some patients to recurrent 
valve infections. 
Patient-specific risk factors for replacement valve 
endocarditis. The identified increased risk of post- 
operative ndocarditis n the younger valve recipient 
likely results from the broader environmental expo- 
sure to potential pathogens experienced by this 
group. In support of this hypothesis, we found a 
correlation between younger age and endocarditis 
with Coxiella burnetii (Q fever), an organism likely to 
infect workers in slaughter houses, usually young 
men. The association of renal dysfunction, com- 
monly seen in patients with dysfunction of other 
organ systems, with increased constant-phase risk 
for endocarditis probably represents the reduced 
resistance to infection in this group of patients. 
Operative risk factors for replacement valve en- 
docarditis. Of particular interest o the surgeon is 
the possibility that choice of a valve replacement 
device can favorably modulate the effects of existing 
(patient-specific) risk factors. Our finding that those 
who received allograft valves had only a single 
constant-phase risk for replacement valve infection 
is consistent with previous reports. 2'11, 14 This nega- 
tion of early-phase risk provides the greatest poten- 
tial for benefit when early risk is expected to be the 
highest, as in the patient with active preoperative 
endocarditis or the patient who requires an aortic 
root replacement. However, in a patient with a 
remote episode of endocarditis (elevated constant 
risk), the allograft valve is not predicted to prevent 
recurrent endocarditis, because its beneficial effects 
are confined to the early phase. 
Although several previous tudies of replacement 
valve endocarditis have grouped different valves on 
the basis of the predominant material in their 
construction (i.e., mechanical, xenograft), in our 
analysis this approach would have masked valve- 
specific differences in risk, perhaps as a result of an 
insufficient number of observations. Indeed, the 
estimated constant-phase risk for valves grouped in 
this manner is not believably different. However, 
when the risk was entered into the analysis individ- 
ually, we found, in addition to differences in now 
"historical" mechanical valves, that those receiving 
the St. Jude Medical valve (n = 505) were at lower 
risk and those receiving Carpentier-Edwards xe- 
nograft valves (n = 1021) were at a higher constant 
risk. The lower constant-phase risk in the St. Jude 
Medical recipients was unexpected and perhaps ex- 
plains why, in a previous analysis of mortality (based 
on many of the same patients in this study group), 
AVR with a St. Jude Medical valve was found to result 
in a lower constant-phase risk of death. 1
That aortic root replacement with a synthetic 
graft was associated with a greatly increased early- 
phase risk, but aortic root replacement with tissue 
(allograft aortic root replacement) was not, suggests 
that it is the placement of the synthetic material, not 
progression of the disease process alone, which 
predisposes patients to postoperative valve infec- 
tion. With this evidence, the need to replace the 
aortic root would favor the use of an allograft valve 
with contiguous replacement of the aortic root, 
especially in the setting of preoperative infection. 
Longer bypass time, although identified previously 
as a correlate for postoperative endocarditis, 1' 11 was 
found in this analysi s to be associated with increased 
constant-phase risk for replacement valve endocarditis, 
whereas the relationship of bypass time to early risk of 
infection, the usual experience in surgery, was weak 
and not believable. Longer bypass time may be a 
surrogate for a group of individually weak associations 
that indicate poor patient condition or more extensive 
disease, such as concomitant procedures, preoperative 
and postoperative organ system dysfunction, number 
of previous aortic valve operations, and New York 
Heart Association class. The increase in risk expected 
for patients with longer bypass time probably repre- 
sents the grouped influence of several individually 
weak risk factors. 
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Association of postoperative complications to re- 
placement valve endocarditis. Although the associ- 
ation of major postoperative wound infections with 
subsequent endocarditis was strong (large coeffi- 
cient) and believable (p < 0.0001), it is unclear 
whether this represents a causal relationship. Re- 
gardless, the patient with a wound infection is at a 
greatly increased risk for subsequent diagnosis of 
prosthetic valve endocarditis, and when it occurs, 
the valve infection is usually caused by the same 
organism. These findings indicate that a patient who 
has a postoperative wound infection after AVR 
should receive aggressive antimicrobial therapy se- 
lected on the basis of positive cultures from the 
infected wound. 
Postoperative cardiac dysfunction was also asso- 
ciated with replacement valve endocarditis. This 
finding may reflect the decreased immunologic tol- 
erance of these patients or the increased bacterio- 
logic challenge imposed by invasive monitoring and 
frequent diagnostic procedures. 
Summary 
Overall, the risk of replacement aortic valve en- 
docarditis was low. When the replacement device 
was an allograft valve the risk was constant; with 
other devices there was an initial peaking risk that 
gave way to a constant risk by about 6 months. 
Compared with the risk of replacement with an 
allograft valw~, the constant risk of endocarditis was 
found to be lower when a St. Jude Medical (mechan- 
ical) valve was used and higher when replacement 
was with a Carpentier-Edwards (xenograft) valve. 
Active preope, rative endocarditis increased both the 
early and the constant risk of recurrent infection, 
whereas remote endocarditis increased only the 
constant-phase risk. When preoperative endocardi- 
tis was caused by Staphylococcus aureus, patients 
were at greater isk of recurrent infection than when 
the preoperative infection was caused by other 
organisms. Patients receiving a concomitant aortic 
root replacement were at increased early risk of 
endocarditis when a synthetic graft was used. A 
culture-positive postoperative wound infection was 
associated with an increased risk of subsequent 
diagnosis of endocarditis; both infections were usu- 
ally caused by the same organism. 
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Discussion 
Dr. Robert B. Karp (Chicago, IIL). The large number of 
patients in this study allows the analysis to approach the 
concept of "truth." The incidence of replacement valve 
endocarditis over a 23-year period was 3.7%, with a mean 
of about 7 years' follow-up. This is a laudably low figure, 
and as the authors point out, it should not be taken as the 
exact figure because of statistical methods that allow 
censoring and reinclusion of patients. 
Some of the concepts elaborated should be reiterated. 
The allograft neutralized the early risk factors for replace- 
ment valve endocarditis. However, what is abundantly 
clear is that the patient is a risk factor, particularly the 
patient with acute or even remote bacterial endocarditis. 
Constant risks were renal dysfunction, younger age, and, 
as noted, healed endocarditis. Disturbingly, the use of a 
synthetic valve conduit was a risk factor, along with the 
well-known factor of Staphylococcus aureus native valve 
endocarditis. 
The authors found that wound infection was associated 
with replacement valve endocarditis. This poses one ques- 
tion: What comes first--a bacteremia caused by the 
mediastinitis that infects the replacement device or a 
bacteremia from other sources that seeds both the wound 
and the replacement device? As noted by the authors, one 
third of patients having bacterial endocarditis as a risk 
factor for replacement device endocarditis had active 
bacterial endocarditis. However, importantly, the remain- 
ing two thirds had remote or inactive endocarditis. Thus 
this prompts a second question. What are the rules and 
inferences for dealing with patients with remote endocar- 
ditis as to the most effective replacement device? 
Young age was a risk factor for replacement valve 
endocarditis. Drug abuse occurs in the younger age 
groups, but this was not an issue in the Brisbane experi- 
ence. There was, however, an association with young age 
and CoxieIla burnetii or Q fever. For the North American 
surgeon, who is not dealing with endemic Q fever, do the 
authors believe young age would remain a risk factor? 
These data suggest again that young patients should 
receive a homograft aortic valve both for the well-known 
advantage of anticoagulation-free, thromboembolism-free 
existence, but also to negate the early risk of replacement 
valve endocarditis. 
Finally, many sm'geons are not homograft enthusiasts. 
Can the authors speculate on the reason for the superi- 
ority of the St. Jude Medical prosthesis over the various 
porcine xenografts with regard to freedom from replace- 
ment valve endocarditis? 
Dr. Aguihotri. Thank you, Dr. Karp, for your questions. 
I will address your comments equentially. 
We did do a separate multivariable analysis in which we 
included some postoperative ariables. Many of you may 
be familiar with the statistical pitfalls of including covari- 
ates that occur after time zero, which in our case was the 
time of AVR. When these variables are identified as risk 
factors, the question of causality will typically arise, as it 
does in the identified association of postoperative wound 
infection and replacement valve endocarditis. I cannot say 
whether the wound infection led to the valve infection or 
whether they were both a result of bacteremia from some 
third source. Nevertheless, we believe that the observation 
does have clinical significance. If a major wound infection 
develops in a valve recipient, our data do indicate an 
important increase in risk for a subsequent diagnosis of 
endocarditis, and we would take aggressive steps to pre- 
vent the appearance of valve infection. 
The distinction between active and remote endocarditis 
as patient-specific risk factors is important. Patients with 
active preoperative endocarditis, defined as culture-posi- 
tive vane infection at operation, were at high risk for 
recurrence arly after operation. Patients with healed 
endocarditis did not have evidence of this early increase in 
risk. These findings, in addition 'to the valve-specific 
difference in risk, lead us to the inference that patients 
with active preoperative endocarditis should receive an 
allograft replacement device. In the patient with remote 
infection, early risk is not increased, and I think that 
factors other than risk of recurrent infection determine 
appropriate valve selection. 
As Dr. Karp points out, one of the interesting aspects of 
this data set, which originated in Australia, was that there 
was a higher prevalence of Coxiella than one would have 
found in a similar American data set. CoxielIa is the 
organism responsible for Q fever, a public health problem 
in Australia that is primarily seen in young men, typically 
workers in slaughter houses. The number of patients in 
our study group with preoperative Coxiella endocarditis 
was 21, or roughly 8% of the total group of preoperative 
valve infections. Among these 21 patients there were only 
three recurrences. These numbers are sufficiently low that 
I do not believe they influenced our results or conclusions. 
The last question regarding why we found modern 
mechanical valves to have a lower long-term resistance to 
infection in some patients than did the allograft valve is a 
fascinating one. We have discussed this issue among 
ourselves at length. What we do know from previous work 
is that the allograft valve is not static over time. There are 
structural changes, and one could hypothesize that these 
could lead to disturbances of flow and surfaces properties 
that could increase the likelihood of bacterial adherence, 
an essential step in the conversion of a bacteremia nto a 
localized valve infection. These changes do not occur in 
mechanical valves, a fact that may explain the observed 
differences in late risk. 
Appendixes 
Appendix I. Variables entered into the multivariate 
analysis 
Demographic variables. Demographic variables were 
age at operation and gender. 
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Clinical variables. Clinical variables included the follow- 
ing: preoperative endocarditis status (yes/no; if yes, native 
valve or prosthetic valve endocarditis), causative organisms 
in patients with preoperative endocarditis, New York Heart 
Association functional class immediately before operation, 
organ system dysfunction before operation (hepatic, pulmo- 
nary, cardiac, renal), and number of previous AVRs. 
Surgical variables. Surgical variables were as follows: 
date of operation, surgeon, valve replacement device, size 
of replacement valve, concomitant procedures, and dura- 
tion of cardiopulmonary bypass. 
Postoperative ariables. Postoperative variables were as 
follows: wound infection (with fever, pain, discharge, inflam- 
mation, and positive results of cultures), postoperative organ 
system dysfunction (cardiac, renal, hepatic, pulmonary), re- 
turns to the operating room for postoperative bleeding, and 
a W postoperative urinary tract infection. 
Note: Hepatic dysfunction was defined as a bilirubin 
level greater than or equal to 35 mmol/L, and renal 
dysfunction was defined as a creatinine level greater than 
or equal to 0.3 mmol/L or a urea concentration greater 
than or equal to 15 mmol/L (or both). Pulmonary dysfunc- 
tion refers to the need for ventilation in the preoperative 
period or the inability to normally discontinue (wean 
from) ventilatory support in the postoperative p riod. 
Appendix II. Parameter estimates from multivariable 
analyses. In the multivariable analysis for replacement 
valve endocarditis n which demographic, linical history, 
and surgical variables were entered, shaping parameters 
for the hazard function were as follows: O = 2.7025, 8 = 0, 
v = 0.2010, m = 1 (corresponding risk factor estimates are 
provided in Table I). In an independent analysis for the 
event replacement valve endocarditis, in which demo- 
graphic, clinical history, surgical, and postoperative ari- 
ables were entered, shaping parameters were as follows: 
P = 2.7025, 6 = 0, v = 0.2010, m = 1 (corresponding risk 
factor estimates are provided in Table II). In a multivari- 
able analysis for the event staphylococcal endocarditis, in
which demographic and clinical history variables were 
entered, shaping parameters were as follows: O = 1.951, 
3 = 0, v = 1.042, m = 0 (corresponding risk factor 
estimates are provided in Table IV). Standard errors of 
estimates and variance-covariance estimates are available 
from us on request. 
Appendix Table 1. Concomitant procedures and non-risk-adjusted prevalence of endocarditis (920 procedures 
performed in 856 operations) 
Endocarditis 
Concomitant procedure n No. % CL (%) 
0.7-1.9 Coronary surgery 515 6 1.2 
Aortic surgery 
Root replacement with graft 53 4 7.5 
Root replacement with tissue 81 2 2.4 
Wall repair or reduction 25 2 8.0 
Arch repair with graft 24 0 0 
Root enlargement 13 0 0 
False aneurysm, closure 15 5 33 
Valve surgery 
Mitral repair 99 8 8.1 5.2-11.9 
Tricuspid repair 5 0 0 0-32 
Myectomy 39 0 0 0-4.9 
Closure of VSD 14 0 0 0-12.8 
Closure of abscess cavity 8 0 0 0-21 
Closure of PDA 5 0 0 0-32 
Repair of LV aneurysm 2 0 0 0-61 
Other cardiac procedure 5 0 0 0-32 
Noncardiac procedure 5 0 0 0-32 
p(x 2) = 0.003 
Total  920 23* 2.8 2.2-3.5 
3.9-13.3 
0.082-5.7 
2.6-17.9 
0-7.7 
0-13.7 
19.4-50 
CL, 70% confidence limits; VSD, ventricular septal defect; PDA, patent ductus arteriosus; LV, left ventricular. 
*Note: Because some patients underwent more than one concomitant procedure, th  sum of preceding rows (27) is greater than the actual number of events 
(23). 
1 7 2 2 Agnihotri et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
December 1995 
Appendix Table 2. Causative organisms in pre- 
replacement endocarditis 
Appendix Table 2. Cont'd. 
Recurrent 
endocarditis: 
Organism n No. 
Recurrent 
endocarditis: 
Organism n No. Staphylococcus sp. 69 15 
ActinobaciIlus 2 1 Staph. aureus 52 13 
Bacillus subtilis 1 0 Staph. epidermidis 12 1 
Brucella sp. 1 0 Unspecified 5 1 
Cardiobacterium hominis 1 0 Streptococcus sp. 96 4 
Corynebacterium sp. 6 1 S. agalactiae 2 0 
C. bovis 1 0 S. bovis 6 0 
C. diphtheriae 2 1 8. faecalis 4 0 
C. xerosis 1 0 S. miUeri 3 0 
Unspecified 2 0 S. mitis 4 0 
CoxieIla burnetii 21 3 S. pneumoniae 1 0 
Diphtheroid sp. 1 0 S. salivarius 3 0 
Eikenella corrodens 1 0 S. sanguis 16 0 
Haemophilus sp. 2 1 S. viridans 38 3 
Klebsiella pneumoniae 2 0 Unspecified 19 1 
Micrococcus p, 2 0 Total 211" 26 
Moraxella lacunata 1 0 *Some patients had polymicrobial nfections, resulting in 211 organisms in 
Mucor sp. 1 1 206 patients. 
Neisseria gonorrhoeae 1 0 
Pseudomonas sp. 2 0 
Appendix Table 3. Patient characteristics and non-risk-adjusted prevalence of r placement valve endocarditis 
(N = 2696 operations; 95 events) 
Endocarditis 
Characteristic n % of2686 No. % CL (%) P(X e) 
Gender 
Male 1982 74 79 4.0 3.5-4.5 0.04 
Female 704 26 16 2.3 1.7-3.0 0.04 
Diabetic 114 4.2 3 2.6 1.5-5.2 0.6 
Preoperative organ system 
dysfunction 
Cardiac (NYHA III-V) 681 25.4 31 4.5 3.7-5.5 0.1 
Renal 123 5.6 9 7.3 4.9-10.6 0.02 
Pulmonary 77 2.9 3 3.9 1.7-7.7 0.9 
Hepatic 59 2.2 4 6.8 3.5-12.0 0,2 
Number of previous AVRs 
None 2352 88 79 3.4 3.0-3.8 
One 290 10.8 13 4.5 3.2-6.1 
Two 43 1.6 3 7.0 3.1-13.5 
Three 1 0.04 0 0 0-85 p(logistic) = 0.2 
Preoperative endocarditis 
Active 91 3.4 12 13.2 9.5-17.9 <0.001 
Remote 152 5.7 18 11.8 9.1-15.2 <0.001 
CL, 70% confidence limits; NYHA, New York Heart Association. 
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Appendix Table 4. Valve replacement device and non-risk-adjusted prevalence of endocarditis 
RepJacement device n % of 2686 No. 
Endocarditis 
% CL (%) 
Autograft 11 0.4 0 0 0-16.0 
Allograft 
Cryopreserved 428 15 11 2.6 1.8-3.6 
Stored at 4 ° C 134 5 6 4.5 2.7-7.2 
Pulmonary 8 0.2 0 0 0-21 
Allovital 1 <0.1 0 0 0-85 
Subtotal 571 21 17 3.0 2.3-4.0 
Mechanical 
St. Jude Medical* 505 18.8 3 0.6 0.2-1.2 
Lillehei-Kaster? 265 9.9 13 4.9 3.5-6.7 
Brunwald-Cutter$ 69 2.6 5 7.3 4.1-12.0 
Bj6rk-Shiley§ 34 1.3 0 0 0-5.5 
Hall-Kasterll 4 0.1 3 75 37-97 
Omniscience? 2 <0.1 0 0 0-9.6 
Hemex¶ 1 <0.i  0 0 0-85 
Subtotal 880 36 24 2.4 2.2-3.4 
Xenograft 
Carpentier-Edwards# 1021 30 38 3.7 3.1-4.4 
Hancock** 71 2.6 2 2.8 0.9-6.5 
Medtronie IntactIJ 43 1.6 2 4.6 1.5-10.7 
Xenotech?t 16 0.6 0 0 0-11.3 
Ionescu-Shiley§ 1 <0.1 0 0 0-85 
Subtotal 1,152 43 42 3.6 3.1-4.3 
Facia lata 72 2.7 12 16.7 12.0-22.5 
Total 2686 100 95 3.5 3.1-3.9 
CL, 70% confidence limits. 
*St. Jude Medical, Inc., St. Paul, Minn. 
?Medical, Inc., Inver Grove Heights, Minn. 
$Cutter Biological, Berkeley, Calif. 
§Shiley, Inc., Irvine, Calif. 
]lMedtronic, Inc., Minneapolis, Minn. 
¶Hcmex Scientific, Inc., Austin, Tex. 
#Baxter Healthcare Corp., Edwards Division, Santa A a,Calif. 
**Johnson & Johnson Cardiovascular, King of Prussia, Pa. 
?fMedtronic Heart Valve Division, Irvine, Calif. 
Appendix Table 5. Validation of multivariable quation." comparison of predicted to actual number of cases of 
replacement valve endocarditis 
Patient charactelqstic 
Replacement valve endocard#is 
Ac~al Predicted* P 
All 95 95 1.0 
Gender 
Male 79 75.5 0.7 
Female 16 19.5 0.4 
Age (yr) 
<50 54 51.1 0.7 
>50 41 43.9 0.7 
No. oJ; previous AVRs 
0 (primary) 79 78.5 0.9 
1 (l]rst re-replacement) 13 12.1 0.8 
2 (second re-replacement) 3 4.3 0.5 
Preoperative endocarditis 
Yes 65 65.6 0.9 
No 30 29.4 0.9 
Valve replacement device 
Mechanical 24 22.8 0.8 
Xenograft 17 18.7 0.7 
Allograft 42 41.2 0.9 
*Predictions from rnultivariable equation depicted in Table I. 
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Appendix Table 6. Redo operation a d prevalence of risk factors 
Primary (n = 2352) 
Risk factor from 
multivariable analysis n % of 2352 
Operation 
Redo (n = 334) 
n % of 334 pO(2) * 
Preoperative endocarditis 183 7.8 60 18 <0.0001 
Active at operation 63 2.7 29 8.7 <0.0001 
Staph. aureus endocarditis 39 1.7 14 4.2 0.002 
Renal dysfunction 96 4.1 27 8.1 0.001 
Aortic root replacement 45 1.9 9 2.7 0.3 
with graft 
Replacement device 
Allograft 534 22.7 48 14.4 <0.0001 
Medtronic Intactt 37 1.6 6 1.8 0.8 
Carpentier-Edwards$ 953 41 58 17.4 <0.0001 
St. Jude Medical§ 389 16.5 116 35 <0.0001 
Fascia lata 54 2.3 18 5.4 0.001 
*p Value is for difference in occurrence of variable between the primary and redo operations. 
tMedtronic, Inc., Minneapolis, Minn. 
SBaxter Healthcare Corp., Edwards Divi ion, Santa Aria, Calif. 
§St. Jude Medical, Inc., St.Paul, Minn. 
Appendix Table 7. Postoperative complications and non-risk-adjusted prevalence of endocarditis 
Endocarditis 
Complication n % of 2686 No. % CL (%) P(x5 
Re-entry for bleeding 129 5 7 5.4 3.4-8.3 0.2 
Wound infection* 53 2 7 13.25 8.3-19.8 <0.001 
Organ system dysfunction 
Cardiac 118 4.4 9 7.6 5.1-11.0 0.05 
Hepatic 51 1.9 6 11.8 7.0-18.4 0.001 
Pulmonary 94 3.5 6 6.4 3.8-10.1 0.13 
Renal 47 1.8 2 4.3 1.4-9.8 0.8 
CL, 70% confidence limits. 
*Includes only those wound infections with positive cultures that were accompanied by fever, woun pain, discharge, and inflammation. 
